Transfer hydrogenation catalysis in cells.
Transfer hydrogenation catalysis in cells.
复制标题
DOI:
10.1039/d0cb00150c
复制
发表时间:
2021-02-01
影响因子:
4.1
通讯作者:
Sadler PJ
中科院分区:
文献类型:
--
作者:
Banerjee S;Sadler PJ
Hydrogenation reactions in biology are usually carried out by enzymes with nicotinamide adenine dinucleotide (NAD(P)H) or flavin mononucleotide (FAMH2)/flavinadenine dinucleotide (FADH2) as cofactors and hydride sources. Industrial scale chemical transfer hydrogenation uses small molecules such as formic acid or alcohols (e.g. propanol) as hydride sources and transition metal complexes as catalysts. We focus here on organometallic half-sandwich RuII and OsII η6–arene complexes and RhIII and IrIII η5–Cpx complexes which catalyse hydrogenation of biomolecules such as pyruvate and quinones in aqueous media, and generate biologically important species such as H2 and H2O2. Organometallic catalysts can achieve enantioselectivity, and moreover can be active in living cells, which is surprising on account of the variety of poisons present. Such catalysts can induce reductive stress using formate as hydride source or oxidative stress by accepting hydride from NAD(P)H. In some cases, photocatalytic redox reactions can be induced by light absorption at metal or flavin centres. These artificial transformations can interfere in biochemical pathways in unusual ways, and are the basis for the design of metallodrugs with novel mechanisms of action. Recent developments in transfer hydrogenation catalysis and photocatalysis in cancer cells by synthetic metal complexes are reviewed. They offer exciting new ways to modulate biochemical pathways for drug development and biotechnology.